Sintx Technologies, Inc. 8-K

What Happened

• On June 29, 2026 Sintx Technologies, Inc. (SINT) entered a Letter Agreement with holder MedTech Ceramics, LP to resolve 507,254 shares that had been held in abeyance after a September 2025 warrant inducement. Under the agreement the Company will promptly issue 255,267 shares from abeyance, replace the remaining 251,987 abeyance shares with a pre-funded common stock purchase warrant, and cancel a September 2025 warrant (760,881 shares) and replace it with a new common stock purchase warrant to buy 1,268,135 shares at $2.14 per share. The Company agreed to file a resale registration statement covering shares issuable upon exercise of the new warrant within 45 days.

Key Details

• Released shares: 255,267 shares of Common Stock issued from abeyance (no additional consideration).
• Pre-Funded Warrant: replaces 251,987 abeyance shares; no expiration date; exercise price was pre-funded in full; exercisable cashlessly; subject to a 9.99% beneficial ownership limit.
• New Warrant: replaces the Holder’s Sept 2025 warrant; exercisable for 1,268,135 shares at $2.14 per share; five-year term; cash or cashless exercise if no effective registration after 90 days; 9.99% beneficial ownership limit; exercise price subject to full-ratchet downward adjustment in dilutive financings (subject to Nasdaq shareholder approval where required).
• Securities treatment: issuances intended to be exempt from registration under Section 4(a)(2) and/or Regulation D. Forms of the Letter Agreement and warrants were filed as exhibits to the 8-K.

Why It Matters

• This transaction is part of Sintx’s effort to manage its capital structure and the balance sheet treatment of shares previously held in abeyance. Issuing some shares and converting others into warrants can affect the company’s reported stockholders’ equity and the timing and form of potential dilution.
• Investors should watch for the Company’s resale registration filing (to be made within 45 days) and any future exercises of the new or pre-funded warrants, which could increase outstanding shares and influence share supply depending on how and when these instruments are exercised.